ALDX vs. IDYA, KNSA, MNKD, SDGR, WVE, AMPH, INDV, DYN, ARDX, and EVO
Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include IDEAYA Biosciences (IDYA), Kiniksa Pharmaceuticals (KNSA), MannKind (MNKD), Schrödinger (SDGR), Wave Life Sciences (WVE), Amphastar Pharmaceuticals (AMPH), Indivior (INDV), Dyne Therapeutics (DYN), Ardelyx (ARDX), and Evotec (EVO). These companies are all part of the "pharmaceutical preparations" industry.
Aldeyra Therapeutics vs.
IDEAYA Biosciences (NASDAQ:IDYA) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.
98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 3.5% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Aldeyra Therapeutics received 341 more outperform votes than IDEAYA Biosciences when rated by MarketBeat users. However, 71.72% of users gave IDEAYA Biosciences an outperform vote while only 69.40% of users gave Aldeyra Therapeutics an outperform vote.
In the previous week, IDEAYA Biosciences had 2 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 3 mentions for IDEAYA Biosciences and 1 mentions for Aldeyra Therapeutics. IDEAYA Biosciences' average media sentiment score of 1.71 beat Aldeyra Therapeutics' score of 0.88 indicating that IDEAYA Biosciences is being referred to more favorably in the media.
IDEAYA Biosciences presently has a consensus price target of $53.58, suggesting a potential upside of 192.73%. Aldeyra Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 57.88%. Given IDEAYA Biosciences' higher possible upside, equities analysts clearly believe IDEAYA Biosciences is more favorable than Aldeyra Therapeutics.
Aldeyra Therapeutics has lower revenue, but higher earnings than IDEAYA Biosciences.
IDEAYA Biosciences' return on equity of -26.74% beat Aldeyra Therapeutics' return on equity.
IDEAYA Biosciences has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.
Summary
IDEAYA Biosciences beats Aldeyra Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Aldeyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aldeyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALDX) was last updated on 3/19/2025 by MarketBeat.com Staff
